Latest news

GSK and Orchard Therapeutics today announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients.

Orchard Therapeutics Scientific Founder Prof Donald Kohn Recognized with Pediatric Blood and Marrow Transplant Consortium Lifetime Achievement Award

Orchard Therapeutics to Present at the Cowen and Company Annual Healthcare Conference